Scott Michael, Jansen Natalie, Bilello Leslie A
Beth Israel Deaconess Medical Center, Department of Emergency Medicine, Boston, Massachusetts.
Clin Pract Cases Emerg Med. 2024 May;8(2):102-106. doi: 10.5811/cpcem.1650.
Ferric derisomaltose is the newest available parenteral iron formulation. Studies have demonstrated a good safety profile with improved tolerability compared to alternative parenteral iron formulations. To date there have been no reported acute, life-threatening cardiac events associated with ferric derisomaltose.
An 86-year-old male who had previously tolerated routine iron infusions received a first dose of ferric derisomaltose at an outpatient infusion clinic. Six minutes into the infusion the patient became unresponsive with no palpable pulse. Return of spontaneous circulation was achieved after two minutes of chest compressions. Electrocardiogram showed complete heart block requiring transcutaneous pacing and vasopressor administration. The patient was transferred to the emergency department for stabilization and then admitted to the cardiac intensive care unit. During admission, the patient received a dual-chamber, permanent pacemaker without complication and was ultimately discharged.
It may be reasonable to consider parenteral iron as a toxicological etiology for patients presenting with complete heart block temporally associated with parenteral iron administration, particularly in patients with underlying conduction abnormalities.
异麦芽糖铁是最新可用的肠外铁制剂。研究表明,与其他肠外铁制剂相比,其安全性良好,耐受性有所提高。迄今为止,尚无与异麦芽糖铁相关的急性、危及生命的心脏事件报告。
一名86岁男性,此前能耐受常规铁剂输注,在门诊输液诊所接受了首剂异麦芽糖铁。输液6分钟后,患者失去反应,脉搏触不到。胸外按压两分钟后恢复自主循环。心电图显示完全性心脏传导阻滞,需要经皮起搏并给予血管加压药。患者被转至急诊科进行稳定治疗,随后收入心脏重症监护病房。住院期间,患者接受了双腔永久起搏器植入,无并发症,最终出院。
对于出现与肠外铁剂给药时间相关的完全性心脏传导阻滞的患者,尤其是有潜在传导异常的患者,将肠外铁剂视为毒理学病因可能是合理的。